3rd ALS Drug Development Summit 2024

Kongressthemen
Identify Transformative ALS Targets, Seek Translational Biomarkers and Propel More Clinical Approvals

Following monumental progress in 2023, the ALS treatment landscape is surging with novel innovation to navigate the complex, multifactorial nature of motor neuron degeneration and develop more truly transformative drugs for sporadic and familial ALS.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2215799-3?pid=4832

Speakers: Diego Cadavid Chief Medical Officer Verge Genomics, Disha Sood Senior Scientist Sanofi , Emily Caporello Director, Small Business Program NINDS/NIH , and more

https://go.evvnt.com/2215799-2?pid=4832

Frau Erin Thomas